Abstract
Advanced inoperable cholangiocarcinomas are among the chemoresistant tumors with a median survival of about 6 months. Fusions in the fibroblast growth factor receptor 2 (FGFR2) gene may be present in up to 50% of patients.
Pemigatinib is a small targeting molecule registered for the treatment of advanced cholangiocarcinomas with the FGFR2 fusion gene. The case report describes the first experience with treatment with this new drug.